Kezar Life Sciences - KZR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.33
  • Forecasted Upside: 176.59 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$6.99
▼ -0.05 (-0.71%)

This chart shows the closing price for KZR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kezar Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KZR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KZR

Analyst Price Target is $19.33
▲ +176.59% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Kezar Life Sciences in the last 3 months. The average price target is $19.33, with a high forecast of $21.00 and a low forecast of $17.00. The average price target represents a 176.59% upside from the last price of $6.99.

This chart shows the closing price for KZR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Kezar Life Sciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/18/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/16/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/13/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/11/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/10/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/10/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/12/2022HC WainwrightBoost TargetBuy$20.00 ➝ $21.00Low
6/28/2022JonestradingBoost Target$17.00 ➝ $20.00Low
6/28/2022Wells Fargo & CompanyBoost TargetOverweight$13.00 ➝ $17.00Low
5/4/2022Wells Fargo & CompanyLower Target$19.00 ➝ $14.00High
4/22/2022Wells Fargo & CompanyReiterated RatingBuy$19.00High
3/18/2022HC WainwrightBoost TargetBuy$20.00 ➝ $22.00High
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$19.00Low
11/16/2021HC WainwrightBoost TargetPositive ➝ Buy$12.00 ➝ $20.00High
8/30/2021HC WainwrightReiterated RatingBuy$12.00High
7/20/2021JonestradingInitiated CoverageBuy$14.00Medium
3/15/2021HC WainwrightReiterated RatingBuy$12.00High
9/22/2020HC WainwrightReiterated RatingBuy$12.00Medium
8/6/2020HC WainwrightReiterated RatingBuy$12.00Medium
6/14/2020CowenReiterated RatingOutperformLow
6/14/2020Wells Fargo & CompanyReiterated RatingOverweight ➝ Market Perform$18.00Low
6/4/2020HC WainwrightReiterated RatingBuy$9.00 ➝ $12.00High
5/5/2020HC WainwrightReiterated RatingBuy$15.00 ➝ $9.00Medium
3/13/2020William BlairReiterated RatingBuyHigh
3/13/2020Wells Fargo & CompanyLower TargetOverweight$30.00 ➝ $18.00High
11/6/2019CowenReiterated RatingBuyMedium
10/21/2019HC WainwrightReiterated RatingBuy$15.00Medium
8/8/2019CowenReiterated RatingBuyHigh
7/29/2019HC WainwrightInitiated CoverageBuy$15.00Low
3/12/2019William BlairReiterated RatingOutperformHigh
7/16/2018Jefferies Financial GroupInitiated CoverageBuy$23.00High
7/16/2018CowenInitiated CoverageOutperformHigh
7/16/2018Wells Fargo & CompanyInitiated CoverageOutperform$30.00High
7/16/2018William BlairInitiated CoverageOutperformHigh
(Data available from 12/10/2017 forward)

News Sentiment Rating

1.19 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/14/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/13/2022
  • 6 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
7/13/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/12/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/11/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/11/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/10/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/10/2022

Current Sentiment

  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Kezar Life Sciences logo
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
Read More

Today's Range

Now: $6.99
Low: $6.87
High: $7.12

50 Day Range

MA: $7.55
Low: $6.39
High: $8.80

52 Week Range

Now: $6.99
Low: $4.30
High: $18.55

Volume

333,108 shs

Average Volume

1,182,984 shs

Market Capitalization

$477.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Kezar Life Sciences?

The following Wall Street sell-side analysts have issued reports on Kezar Life Sciences in the last twelve months: HC Wainwright, Jonestrading, and Wells Fargo & Company.
View the latest analyst ratings for KZR.

What is the current price target for Kezar Life Sciences?

3 Wall Street analysts have set twelve-month price targets for Kezar Life Sciences in the last year. Their average twelve-month price target is $19.33, suggesting a possible upside of 176.6%. HC Wainwright has the highest price target set, predicting KZR will reach $21.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $17.00 for Kezar Life Sciences in the next year.
View the latest price targets for KZR.

What is the current consensus analyst rating for Kezar Life Sciences?

Kezar Life Sciences currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KZR will outperform the market and that investors should add to their positions of Kezar Life Sciences.
View the latest ratings for KZR.

What other companies compete with Kezar Life Sciences?

How do I contact Kezar Life Sciences' investor relations team?

Kezar Life Sciences' physical mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 822-5600 and its investor relations email address is [email protected] The official website for Kezar Life Sciences is www.kezarlifesciences.com. Learn More about contacing Kezar Life Sciences investor relations.